Home Innovation Medical Technology VentriJect Raises €1.7M, ...

VentriJect Raises €1.7M, Expanding VO₂ Medical Tech Worldwide

Medical Technology

Business Honor - VentriJect Secures €1.7M for Global VO₂ Tech

Business Honor
13 August, 2025

VentriJect raised €1.7M to expand the VO₂ max device across Europe and into the US healthcare centers and fitness markets.

VentriJect, a Danish health technology business, has raised €1.7 million in order to fund its expansion into the US along with further expansion across Europe. Investment round was mostly supported by current investors, like business angels and venture capital firms. The Export and Investment Fund of Denmark (EIFO), which has supported the business since 2021, is one of its main investors.

Seismofit, a CE-marked healthcare device that examines VO₂ max, a crucial indicator of cardiorespiratory fitness, was created by VentriJect, a 2018 spinout from Aalborg University. In contrast to conventional examinations, Seismofit detects minute vibrations in the chest carried on by heartbeats using seismocardiography. Without the need for activity, it offers an accurate VO₂ max value in just three minutes. In a recent BBC broadcast, the device was praised for its accuracy when compared with clinical CPET tests and has both healthcare and fitness applications.

VentriJect has grown quickly since launching its commercial product, gaining agreements for distribution in the UK, Denmark, the Netherlands, Sweden, and Switzerland. In addition, the business is in final discussions with major European healthcare providers. According to CEO Mikkel Kristiansen, the access to more than 55,000 healthcare centers and the largest fitness market in the world is entering the US as its logical next step.

Anders Throup-Jensen of EIFO stated, "We are eager to continue our support for VentriJect. We believe the team can lead the VO₂ max test space worldwide because they showed excellent production and market entrance capabilities.” Highlighting a €48 million investment into the HealthCap IX fund from Novo Holdings and EIFO, Kristiansen additionally pointed out the growing interest of investors in Nordic healthtech. He believes medical technology is just getting started since innovation is quick.